Status:
COMPLETED
Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia
Lead Sponsor:
Liaquat University of Medical & Health Sciences
Collaborating Sponsors:
University of Urbino "Carlo Bo"
Conditions:
Hyperuricemia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can sig...
Detailed Description
Uric acid, a metabolic byproduct of purine degradation in humans, is a significant risk factor for the development of gout and type 2 diabetes. Supplementation with quercetin, a flavonol not naturally...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Aged between 18 and 75 years.
- Diagnosed with obesity.
- Diagnosed with hypercholesterolemia.
- With or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dL).
- No restrictions on BMI, alcohol consumption, or smoking habits.
- Exclusion criteria:
- Current use of uric acid-lowering medications (e.g., allopurinol, febuxostat).
- Diagnosed with oncological diseases.
- Diagnosed with neurological diseases.
- Diagnosed with inflammatory bowel diseases.
Exclusion
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06591767
Start Date
October 1 2023
End Date
August 31 2024
Last Update
October 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
S. Orsola-Malpighi Polyclinic Hospital
Bologna, Italy